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ObituaryRenato Dulbecco:
A Renaissance ScientistRenato Dulbecco died on February 19,
2012, three days shy of his 98th birthday.
He had a remarkable career in science
that spanned over 60 years. In 1948 he
published, with Salvador Luria, his first
real scientific paper in Genetics on bacte-
riophage genetics and in 2008 published
his last paper in PNAS on breast cancer
tumor-initiating cells. In the intervening
years, Dulbecco helped to decipher how
tumor viruses integrate into genomes
and transform normal cells into cancer
cells and propelled biology into the
genomic era with his broad thinking and
prescient foresight.
Dulbecco was born in Cantanzaro in
Southern Italy in 1914. He trained as a
medical doctor, specializing in pathology,
and received his degree from the Univer-
sity of Torino in 1936. After graduating,
he served 2 years in the military, before
returning to train in pathology. He then
decided that he was more interested in
basic research than medicine and began
working on cell culture techniques withRenato DulbeccoGiuseppe Levi in his institute in
Torino.
At the start of World War II,
Dulbecco was called up again. He
fought on the Russian front and was
seriously wounded, leading to his
discharge. After the German occu-
pation of Italy, he joined the resis-
tance, acting as physician for local
partisanunits in thePiemonte region.
Following the war Dulbecco
enrolled again at the university to
take physics courses and then re-
turned to the Levi Institute, where
hehadalreadymetRita Levi-Montal-
cini and Salvador Luria, who were
fellow students. Luria had been in
the USA since the beginning of the
war, and he and Levi-Montalcini
urged Dulbecco to move to the US
to pursue his dream of working on
the genetics of a simple organism.
At the invitation of Luria, who was
working on T series coliphages at
Indiana University, Bloomington,
Dulbecco joined Luria in 1947.In 1949 Dulbecco moved to a junior
faculty position at Caltech, where he con-
tinued to study bacteriophage, making
use of his physics and mathematics
training to analyze phage growth, recom-
bination, and UV reactivation in a rigorous
quantitative fashion. A donor had pro-
vided Caltech with a fund for studies
in animal viruses, and this prompted
Dulbecco to apply the lessons he had
had learned from his phage work to
the study of animal viruses, beginning
with Western equine encephalomyelitis
(WEE) virus and then turning to poliovirus,
a major health problem at the time.
Together with Marguerite Vogt, who
became his long-term colleague, Dul-
becco developed the first quantitative
assays for animal viruses, setting up
a plaque assay to measure WEE and
poliovirus titers.
Howard Temin, a student in Dulbecco’s
lab, and Harry Rubin, a postdoctoral
fellow, were working on Rous sarcoma
virus at the time, and this piquedCellDulbecco’s interest in tumor viruses. He
decided to work on the polyomaviruses,
which constituted one of the growing
number of viruses that could elicit
tumors in animals. Dulbecco hoped that
by studying these simple DNA tumor
viruses he might be able to gain insights
into the origins of human cancer.
He began his quest in the late 1950s by
using two viruses: polyomavirus, a rodent
tumor virus that was isolated by Stewart
and Eddy in 1958 in a follow up of Ludwig
Gross’ earlier work; and SV40, a related
simian virus discovered as a contaminant
in batches of polio vaccine in 1959.
Dulbecco’s first paper on polyomaviruses
described the ability of polyomavirus
to cause plaques in mouse embryonic
kidney cells in culture. It was published
in 1959, and it provided the first way
to measure polyomavirus titers. Subse-
quent papers with Marguerite Vogt char-
acterized virus-cell interactions. They
showed that when polyomavirus in-
fects mouse embryo cells, the cells
become transformed and produce virus,
whereas when hamster embryo cells are
infected, they are transformed but do
not produce virus, which is consistent
with the ability of polyomavirus to cause
tumors in hamsters. Vogt and Dulbecco
also demonstrated that polyomavirus149, Mcontains DNA and has a circular
genome.
Intrigued by Jonas Salk’s vision
for a new type of research institute,
Dulbecco decided to join the Salk
Institute in La Jolla as one of
the founding fellows. He and Vogt
moved to the Salk Institute in late
1963. While the main institute build-
ings were being constructed, they
set up their laboratory in the tempo-
rary facilities in a series of trailers
on the site (which are still there!),
where they worked for the next
2 years before finally moving into
the brand new laboratories in the
north wing of the iconic Salk building
on the bluffs overlooking the Pacific
Ocean.
Dulbecco quickly attracted a
series of outstanding postdoctoral
fellows to work on polyomaviruses
as a model for human cancer. A
string of important papers followed.
With Lee Hartwell, he showed that
polyomavirus infection of mousearch 30, 2012 ª2012 Elsevier Inc. 9
cells induces cellular DNA synthesis,
which is a prerequisite for the virus to
replicate its own DNA. With Heiner West-
phal and Joe Sambrook, Dulbecco
discovered that polyoma- and SV40-
transformed cells express viral RNA and
contain viral DNA sequences stably inte-
grated into the host DNA. With Walter
Eckhart, he showed that some tempera-
ture-sensitive polyomavirus mutants elicit
temperature-dependent transformation
of cells, implying that the continuous
presence of a virally-encoded protein is
required for transformation. These semi-
nal findings argued strongly against the
idea that tumor viruses transform cells
by a hit-and-run mechanism. Dulbecco
trained a truly stellar group of scientists
during this period, most of whom went
on to have extremely successful careers.
In 1972, Dulbecco left the Salk Institute
to become Assistant Director of Research
at the Imperial Cancer Research Fund
(ICRF) in London. His departure left
8,000 square feet of vacant laboratory
space at the Salk. This provided the
opportunity to hire the first Assistant
Professors at the Institute to work on
tumor viruses. These appointments
created the Tumor Virology Laboratory,
whose legacy is still in evidence at the
Institute today. At ICRF, Dulbecco
continued to investigate polyomavirus
transformation. He and Yoshi Ito charac-
terized the viral proteins, calledTantigens,
which are produced early in infection and
are responsible for transformation. In
particular, Dulbecco and Ito were the first
to show that the virus expresses three
distinct T antigens and that the middle-
sized T antigen, which by itself can trans-
formfibroblasts, ismembrane associated.
For his pioneering work on the mecha-
nisms of tumor viruses, Dulbecco shared
the 1975 Nobel Prize in Physiology or10 Cell 149, March 30, 2012 ª2012 Elsevier IMedicine with Temin and David Balti-
more, who both had trained with Dul-
becco at different times. Dulbecco’s
work on DNA tumor viruses influenced
a whole generation and many of his
trainees and their descendants populated
the burgeoning field of tumor virology. His
instinct that tumor viruses would provide
insights into human cancer proved
prescient and subsequent work on SV40
and polyomavirus transforming proteins
pinpointed several key growth control
pathways that are activated by mutations
in cancer cells, such as tyrosine phos-
phorylation.
Dulbecco returned to the Salk Institute
in 1977 to begin an entirely new program
in mammary carcinogenesis and used
the newly developed monoclonal anti-
body technology to identify surface
proteins on normal mammary cells. This
allowed him to identify several different
types of mammary cells and to define
possible roles for these cells in normal
mammary development. This also en-
abled him to study how mutagens might
perturb the normal function of these cells
in the gland to initiate carcinogenesis.
Dulbecco closed his laboratory in 1988,
when asked to assume the presidency of
the Salk Institute, a position in which he
served with great distinction for four
years. Subsequently, Dulbecco spent
time in Italy organizing an Italian genome
project, which ultimately failed, and
heading a group at the Istituto Tecnologie
Biomediche-Consiglio Nazionale delle
Richerche in Milan working on mammary
cancer.
Dulbecco recognized early on that
mutations are likely to play an important
role in carcinogenesis, and he speculated
on that possibility in his 1975 Nobel
Lecture. His sense of biology’s place in
society was already evident in his Nobelnc.Lecture, in which he pointed out the
general public disregard of the cancer
risks posed by tobacco smoking and
other man-made carcinogens. He real-
ized that it would be necessary to define
all the genes expressed both in normal
and cancer cells and then pinpoint
cancer-specific genetic changes if one
wanted to fully understand the causes of
the disease and develop better treat-
ments. This thinking led him to propose
in two lectures in 1985 and 1986, and
subsequently in an influential letter to
Science in 1986, that an effort to
sequence the human genome should be
undertaken. Others had thought that this
might be valuable and even feasible
because of the advances in high-through-
put sequencing methods, which were
becoming available at the time. However,
it took someone of Dulbecco’s stature
to bring this to the public attention and
galvanize efforts in this direction. This
ultimately led to the human genome
project and the completion of the
human genome sequence in 2001. As
Dulbecco predicted, the genetic differ-
ences between normal somatic cells and
cancer cells revealed by sequencing
have greatly illuminated our under-
standing of the disease.
Dulbecco lived through an amazing
period of biological discovery; his career
began before the structure of DNA was
known and ended after the complete
sequence of the human genome had
been determined and was beginning to
be used for the diagnosis and treatment
of cancer, a disease he had set out to
conquer nearly 50 years earlier. Dulbecco
had a broader vision of science than most
and a keen instinct for important prob-
lems to solve. His worked influenced
a whole generation of biologists—he
was truly a renaissance scientist.Tony Hunter1,*
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